Imaging Standard Established for Cardiac Amyloidosis
Experts have confirmed that SPECT/CT imaging is the reliable, noninvasive way to diagnose transthyretin cardiac amyloidosis.
Updated on Sept. 22, 2026 in Heart Disease
Live Poll
Do you trust established medical diagnostic procedures more than emerging experimental testing methods?
Medical experts recently identified SPECT/CT imaging as the gold standard for noninvasively diagnosing transthyretin cardiac amyloidosis. This approach is increasingly critical as heart failure patients may face this condition in 13% of cohorts, while 10% of those with aortic stenosis are also affected.
Why it matters
The rise of effective disease-modifying therapies makes accurate, earlier detection of cardiac amyloidosis essential for patient care. Using noninvasive imaging helps clinicians confirm diagnoses without more invasive procedures.
Clinical consensus identifies SPECT/CT as the standard for noninvasively diagnosing transthyretin cardiac amyloidosis by identifying bone-avid tracer uptake. While this diagnostic approach is established, PET imaging tracers like iodine-124 evuzamitide remain under investigation.
The players
Japan
This country is a source of medical research regarding cardiac amyloidosis diagnostic tools.
France
This country serves as a center for the research and development of advanced cardiac imaging techniques.
The details
Cardiac amyloidosis occurs when misfolded proteins accumulate within the heart muscle, interfering with function. SPECT/CT works by visualizing bone-avid tracers like Technetium-99m PYP, which successfully highlights these deposits while filtering out background blood-pool noise. By contrast, investigational PET tracers, such as iodine-124 evuzamitide, require a 4 to 5 hour wait to clear the blood-pool before the myocardium can be assessed.
Timeline
September 22, 2026: Experts reviewed cardiac amyloidosis imaging standards during a webinar.
Health Landscape
The clinical standard for cardiac amyloidosis imaging has shifted to accommodate the arrival of new disease-modifying therapies. This evolution in diagnostics aims to replace traditional methods with precise, noninvasive imaging that guides complex treatment pathways.
If you have been diagnosed with heart failure or aortic stenosis, discuss with your doctor whether imaging to rule out amyloidosis is appropriate for your care. Knowing your specific subtype of cardiac amyloidosis—whether immunoglobulin light-chain or transthyretin—is essential for understanding your treatment options.
The takeaway
Cardiac amyloidosis requires timely diagnosis to benefit from modern medical interventions. Patients should work with their cardiology team to determine if diagnostic imaging is necessary given their specific heart history or symptoms.
Further reading
For more on managing heart conditions, visit the Heart Disease section.
Source note: This article includes information reported by AuntMinnieEurope.
Live Poll
Do you trust established medical diagnostic procedures more than emerging experimental testing methods?
